Rani Therapeutics Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
RANI$0.56-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(67,883) | $(63,344) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 19,008 | 15,782 |
| Depreciation and amortization | 822 | 548 |
| Non-cash operating lease expense | 1,041 | 764 |
| Amortization of debt discount and issuance costs | 232 | 77 |
| Net accretion and amortization of investments in marketable securities | (2,316) | (851) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 282 | 505 |
| Other assets | (245) | — |
| Accounts payable | (595) | 163 |
| Accrued expenses and other current liabilities | (540) | 605 |
| Operating lease liabilities | (1,042) | (764) |
| Net cash used in operating activities | (51,236) | (46,515) |
| Cash flows from investing activities | ||
| Proceeds from maturities of marketable securities | 104,350 | 3,000 |
| Purchases of marketable securities | (73,261) | (73,817) |
| Purchases of property and equipment | (1,229) | (1,619) |
| Net cash provided by (used in) investing activities | 29,860 | (72,436) |
| Cash flows from financing activities | ||
| Issuance of common stock under employee stock purchase plan | 355 | 271 |
| Proceeds from employee stock purchase plan | 40 | 46 |
| Tax withholdings paid on behalf of employees for net share settlement | (162) | (626) |
| Proceeds from the issuance of long-term debt and warrants, net of issuance costs | — | 29,574 |
| Payment of deferred financing costs | — | (260) |
| Net cash provided by financing activities | 233 | 29,005 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (21,143) | (89,946) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 27,507 | 117,453 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $6,364 | $27,507 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | $4,182 | $730 |
| Cash paid for income taxes | $35 | $48 |
| Supplemental disclosures of non-cash investing and financing activities | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $578 | $514 |
| Exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC | $169 | $78,487 |
| Interest income receivable included in prepaid expenses | $148 | $44 |
| Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities | $18 | $355 |
| Issuance of costs deducted from long-term debt proceeds | $— | $851 |
| Deferred financing costs included in prepaid expenses | $— | $260 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.